Literature DB >> 18604714

Protein kinase C signalling in leukemia.

Amanda J Redig1, Leonidas C Platanias.   

Abstract

The protein kinase C (PKC) family of proteins includes several kinases that share structural homology, but at the same time exhibit substantial functional diversity. There is a significant amount of evidence establishing distinct patterns of expression and function for different PKC isoforms and groups in different leukemias. Although most members of this family promote leukemic cell survival and growth, others exhibit opposing effects and participate in the generation of antileukemic responses. This review summarizes work in this field on the relevance of distinct members of the PKC family in the pathophysiology of myeloid and lymphoid leukemias. The clinical-therapeutic potential of such ongoing work for the treatment of future development of novel approaches for the treatment of different types of leukemias is discussed.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18604714     DOI: 10.1080/10428190802007726

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN: 1026-8022


  10 in total

1.  Targeting PKC-mediated signal transduction pathways using enzastaurin to promote apoptosis in acute myeloid leukemia-derived cell lines and blast cells.

Authors:  Peter P Ruvolo; Liran Zhou; Julie C Watt; Vivian R Ruvolo; Jared K Burks; Tilahun Jiffar; Steven Kornblau; Marina Konopleva; Michael Andreeff
Journal:  J Cell Biochem       Date:  2011-06       Impact factor: 4.429

2.  Protein Kinase C Epsilon Overexpression Is Associated With Poor Patient Outcomes in AML and Promotes Daunorubicin Resistance Through p-Glycoprotein-Mediated Drug Efflux.

Authors:  Rachael Nicholson; Ana Catarina Menezes; Aleksandra Azevedo; Adam Leckenby; Sara Davies; Claire Seedhouse; Amanda Gilkes; Steve Knapper; Alex Tonks; Richard L Darley
Journal:  Front Oncol       Date:  2022-05-30       Impact factor: 5.738

3.  Activation of protein kinase C{eta} by type I interferons.

Authors:  Amanda J Redig; Antonella Sassano; Beata Majchrzak-Kita; Efstratios Katsoulidis; Hui Liu; Jessica K Altman; Eleanor N Fish; Amittha Wickrema; Leonidas C Platanias
Journal:  J Biol Chem       Date:  2009-02-11       Impact factor: 5.157

4.  Role for PKC δ in Fenretinide-Mediated Apoptosis in Lymphoid Leukemia Cells.

Authors:  Vivian R Ruvolo; Kul B Karanjeet; Todd F Schuster; Rhoderick Brown; Yibin Deng; Edward Hinchcliffe; Peter P Ruvolo
Journal:  J Signal Transduct       Date:  2010-01-01

5.  Targeting TOR dependence in cancer.

Authors:  Matthew R Janes; David A Fruman
Journal:  Oncotarget       Date:  2010-05

6.  The protein kinase C agonist PEP005 (ingenol 3-angelate) in the treatment of human cancer: a balance between efficacy and toxicity.

Authors:  Elisabeth Ersvaer; Astrid Olsnes Kittang; Peter Hampson; Kristoffer Sand; Bjørn Tore Gjertsen; Janet M Lord; Oystein Bruserud
Journal:  Toxins (Basel)       Date:  2010-01-22       Impact factor: 4.546

Review 7.  Deregulation of Interferon Signaling in Malignant Cells.

Authors:  Efstratios Katsoulidis; Surinder Kaur; Leonidas C Platanias
Journal:  Pharmaceuticals (Basel)       Date:  2010-02-04

Review 8.  Digging deep into "dirty" drugs - modulation of the methylation machinery.

Authors:  Lisa Pleyer; Richard Greil
Journal:  Drug Metab Rev       Date:  2015-01-08       Impact factor: 4.518

Review 9.  Diverse Impacts of HIV Latency-Reversing Agents on CD8+ T-Cell Function: Implications for HIV Cure.

Authors:  Genevieve Tyndale Clutton; R Brad Jones
Journal:  Front Immunol       Date:  2018-06-22       Impact factor: 7.561

10.  Dual Targeting of Stromal Cell Support and Leukemic Cell Growth by a Peptidic PKC Inhibitor Shows Effectiveness against B-ALL.

Authors:  Paola Fernanda Ruiz-Aparicio; Natalia-Del Pilar Vanegas; Gloria Inés Uribe; Paola Ortiz-Montero; Camila Cadavid-Cortés; Jimmy Lagos; Jessica Flechas-Afanador; Adriana Linares-Ballesteros; Jean-Paul Vernot
Journal:  Int J Mol Sci       Date:  2020-05-25       Impact factor: 5.923

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.